NEULANDLAB Neuland Laboratories Q2 FY26 results (Jul–Sep 2025) and concall
Neuland Labs delivered a record-breaking performance in Q2 FY26, with revenue and profitability soaring due to strong execution in its commercial CMS business. The impressive top-line growth of 63.7% and an EBITDA margin of 30.4% highlight significant operating leverage. However, this rapid growth strained working capital, leading to higher inventory, increased receivables, and negative cash flow. Management remains confident in the full-year outlook, emphasizing the long-term potential of its peptide facility investments and a strengthening project pipeline, while cautioning investors about t
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 65.3%, net profit up 200.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 311 | 398 | 328 | 293 | 514 +65% |
| EBITDA | 61 | 86 | 51 | 34 | 155 +154% |
| Net profit | 32 | 101 | 28 | 14 | 96 +200% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
